Our partnership with King’s College London allows us to deliver considerable synergies by providing the UK’s only academically-run translational research unit, which allows cross pollination of expertise, technology and translational research between different types of advanced therapies.

Our NIHR BRC’s unique platform infrastructure, together with industry expertise of our partners Innovate UK and Cell and Gene Therapy Catapult enables us at the ATA to improve production facilities for cell therapies and for retro-, lenti- and adenoviral vectors to scale and quality to meet demand.

With its launch the Accelerator completes our ‘end to end’ centre of excellence for gene and cell therapies. We are now poised to deliver on our strategy of accelerating the development of advanced therapies into clinical settings where they can benefit patients.